Gapping up
In reaction to strong earnings/guidance: ACW +8.7%, RYAAY +4.9%, RPM +2.1%.
M&A news: FDO +24.3% (still checking), DLTR +8.8% (still checking).
Other news: XGTI +25.1% (awarded subcontract by CACI (CACI) on Multiple-Award Contract to provide communications and networking services to U.S. Army), LOCO +7.4% (continued momentum from last weeks IPO), KNDI +3.3% (strong Shanghai market overnight), FSLR +2.8% (co and and XSOL establish supply agreement in Japan), ADXS +2.4% (receives notice of allowance for cancer immunotherapies patent in Japan), OMER +2.3% (positive mention Mad Money), GLPI +1.7% (positive mention Mad Money), PT +1.3% (Moody's upgrades Portugal's government bond rating), ACH +1.3% (still checking), PLUG +1.3% (continued momentum), CYRN +0.9% (confirms terms of registered direct offering of ordinary shares and warrants), FTR +0.7% (FCC approves Frontier's acquisition of AT&T's (T) Connecticut wireline operations), GSK +0.7% (indicated its possible to spin off consumer division, according to reports ).
Analyst comments: NERV +3.4% (initiated with a Buy at Jefferies, with a Outperform at Robert W. Baird), WCG +3.1% (upgraded to Buy from Neutral at Goldman), JNPR +2.1% (upgraded to Outperform from Mkt Perform at Bernstein), XRX +1.1% (upgraded to Neutral from Underweight at JP Morgan)
In reaction to strong earnings/guidance: ACW +8.7%, RYAAY +4.9%, RPM +2.1%.
M&A news: FDO +24.3% (still checking), DLTR +8.8% (still checking).
Other news: XGTI +25.1% (awarded subcontract by CACI (CACI) on Multiple-Award Contract to provide communications and networking services to U.S. Army), LOCO +7.4% (continued momentum from last weeks IPO), KNDI +3.3% (strong Shanghai market overnight), FSLR +2.8% (co and and XSOL establish supply agreement in Japan), ADXS +2.4% (receives notice of allowance for cancer immunotherapies patent in Japan), OMER +2.3% (positive mention Mad Money), GLPI +1.7% (positive mention Mad Money), PT +1.3% (Moody's upgrades Portugal's government bond rating), ACH +1.3% (still checking), PLUG +1.3% (continued momentum), CYRN +0.9% (confirms terms of registered direct offering of ordinary shares and warrants), FTR +0.7% (FCC approves Frontier's acquisition of AT&T's (T) Connecticut wireline operations), GSK +0.7% (indicated its possible to spin off consumer division, according to reports ).
Analyst comments: NERV +3.4% (initiated with a Buy at Jefferies, with a Outperform at Robert W. Baird), WCG +3.1% (upgraded to Buy from Neutral at Goldman), JNPR +2.1% (upgraded to Outperform from Mkt Perform at Bernstein), XRX +1.1% (upgraded to Neutral from Underweight at JP Morgan)